Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 33.

Gerber, P A; Spinas, G A; Berneis, K (2012). Small dense low-density lipoprotein particles: priority as a treatment target in type 2 diabetes? Diabetes Management, 2(1):65-74.

Berneis, K (2012). Die Suche nach dem süssen Plazebo. Zucker ist nicht gleich Zucker! Swiss Medical Forum, 12(1-2):6-7.

Mikhailidis, D P; Elisaf, M; Rizzo, M; Berneis, K; Griffin, B; Zambon, A; Athyros, V; de Graaf, J; März, W; Parhofer, K G; Rini, G B; Spinas, G A; Tomkin, G H; Tselepis, A D; Wierzbicki, A S; Winkler, K; Florentin, M; Liberopoulos, E (2011). "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Current Vascular Pharmacology, 9(5):533-571.

Mikhailidis, D P; Elisaf, M; Rizzo, M; Berneis, K; Griffin, B; Zambon, A; Athyros, V; de Graaf, J; März, W; Parhofer, K G; Rini, G B; Spinas, G A; Tomkin, G H; Tselepis, A D; Wierzbicki, A S; Winkler, K; Florentin, M; Liberopoulos, E (2011). "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Executive summary. Current Vascular Pharmacology, 9(5):531-532.

Aeberli, I; Gerber, P A; Hochuli, M; Kohler, S; Haile, S R; Gouni-Berthold, I; Berthold, H K; Spinas, G A; Berneis, K (2011). Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: a randomized controlled trial. American Journal of Clinical Nutrition, 94(2):479-485.

Berneis, K; Rizzo, M; Evans, J; Rini, G B; Spinas, G A; Goedecke, J H (2010). Interleukin-18 levels are associated with low-density lipoproteins size. European Journal of Clinical Investigation, 40(1):54-55.

Ozbalkan, Z; Efe, C; Cesur, M; Ertek, S; Nasiroglu, N; Berneis, K; Rizzo, M (2010). An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis, 212(2):377-382.

Goedecke, J H; Utzschneider, K; Faulenbach, M V; Rizzo, M; Berneis, K; Spinas, G A; Dave, J A; Levitt, N S; Lambert, E V; Olsson, T; Kahn, S E (2010). Ethnic differences in serum lipoproteins and their determinants in South African women. Metabolism: Clinical and Experimental, 59(9):1341-1350.

Berneis, K; Rizzo, M; Berthold, H K; Spinas, G A; Krone, W; Gouni-Berthold, I (2010). Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. European Heart Journal, 31(13):1633-1639.

Rizzo, M; Spinas, G A; Rini, G B; Berneis, K (2010). Is diabetes the cost to pay for a greater cardiovascular prevention? International Journal of Cardiology, 144(2):309-310.

Berneis, K (2010). Mangelernährung an Schweizer Spitälern - heisses Eisen oder heisse Luft? Swiss Medical Forum, (10):191-192.

Kohler, S; Thalhammer, C; Berneis, K (2010). Medikamentöse Therapie von Mikrozirkulationsstörungen. Altbewährtes und Neues. Swiss Medical Forum, 10(42):725-728.

Kiencke, S; Handschin, R; von Dahlen, R; Muser, J; Brunner-Larocca, H P; Schumann, J; Felix, B; Berneis, K; Rickenbacher, P (2010). Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. European Journal of Heart Failure, 12(9):951-957.

Rizzo, M; Berneis, K; Koulouris, S; Pastromas, S; Rini, G B; Sakellariou, D; Manolis, A S (2010). Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes? International Journal of Clinical Practice, 64(12):1632-1642.

Rizzo, M; Berneis, K (2010). The role of small, dense LDL in cardiovascular risk: The contributions of the universities of Palermo and Zurich. Frontiers in Cardiovascular Drug Discovery, 1:96-104.

Rizzo, M; Pernice, V; Frasheri, A; Di Lorenzo, G; Rini, G B; Spinas, G A; Berneis, K (2009). Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clinical Endocrinology, 70(6):870-875.

Rizzo, M; Rini, G B; Spinas, G A; Berneis, K (2009). The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes? Atherosclerosis, 204(2):330-333.

Rizzo, M; Krayenbühl, P A; Pernice, V; Frasheri, A; Battista Rini, G; Berneis, K (2009). LDL size and subclasses in patients with abdominal aortic aneurysm. International Journal of Cardiology, 134(3):406-408.

Rizzo, M; Berneis, K; Hersberger, M; Pepe, I; Di Fede, G; Rini, G B; Spinas, G A; Carmina, E (2009). Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Human Reproduction, 24(9):2286-2292.

Rizzo, M; Kotur-Stevuljevic, J; Berneis, K; Spinas, G; Rini, G B; Jelic-Ivanovic, Z; Spasojevic-Kalimanovska, V; Vekic, J (2009). Atherogenic dyslipidemia and oxidative stress: a new look. Translational Research, 153(5):217-223.

Berneis, K; Rizzo, M; Hersberger, M; Rini, G B; Di Fede, G; Pepe, I; Spinas, G A; Carmina, E (2009). Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. International Journal of Clinical Practice, 63(1):56-62.

Rizzo, M; Spinas, G A; Cesur, M; Ozbalkan, Z; Rini, G B; Berneis, K (2009). Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis, 207(2):502-506.

Rizzo, M; Rizvi, A A; Spinas, G A; Rini, G B; Berneis, K (2009). Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opinion on Investigational Drugs, 18(10):1495-1503.

Arrigoni, E; Amadò, R; Sieber, R; Reinli, K; Laimbacher, J; L'Allemand-Jander, D; Marx, G; Imfeld, T; Nebiker-Pedrotti, P; Nordmann, H; Keller, U; Colombani, P C; Ballmer, P E; Berneis, K; Laederach-Hofmann, K; Fäh, D (2009). Kohlenhydrate in der Ernährung. Stellungnahme und Empfehlungen der Eidgenössischen Ernährungskommission (EEK) 2009. Zürich: Eidgenössische Ernährungskommission (EEK).

Rizzo, M; Berneis, K; Spinas, G A; Rini, G B; Carmina, E (2009). Long-term consequences of polycystic ovary syndrome on cardiovascular risk. Fertility and Sterility, 91(4 Supp):1563-1567.

Rizzo, M; Berneis, K; Spinas, G A; Rini, G B; Kapur, N K (2009). Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance? International Journal of Clinical Practice, 63(3):478-485.

Berneis, K; Rizzo, M; Spinas, G A; Di Lorenzo, G; Di Fede, G; Pepe, I; Pernice, V; Rini, G B (2009). The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis. Clinica Chimica Acta, 406(1-2):36-40.

Krayenbuehl, P A; Wiesli, P; Schmid, C; Lehmann, R; Spinas, G A; Berneis, K (2008). Insulin sensitivity in type 2 diabetes is closely associated with LDL particle size. Swiss Medical Weekly, 138(19-20):275-280.

Rizzo, M; Berneis, K; Carmina, E; Rini, G B (2008). How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? American Journal of Obstetrics and Gynecology, 198(1):28.e1-28.e5.

Rizzo, M; Berneis, K; Altinova, A E; Toruner, F B; Akturk, M; Ayvaz, G; Rini, G B; Spinas, G A; Arslan, M (2008). Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes. Diabetic Medicine, 25(12):1406-1411.

Elke, B; Käser, L; Berneis, K; Spinas, G (2008). Diabetes mellitus - Diagnose und Blutzuckerkontrolle. Praxis, 97(10):529-538.

Rizzo, M; Trepp, R; Berneis, K; Christ, E R (2008). Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency. Growth Hormone & IGF Research, 18(3):264-266.

Rizzo, M; Christ, E R; Rini, G B; Spinas, G A; Berneis, K (2008). The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? Expert Opinion on Pharmacotherapy, 9(13):2295-2303.

This list was generated on Fri Sep 22 01:16:06 2017 CEST.